Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (34 ops.)
Latest filing published 17 Sept 2026 for Travere Therapeutics, Inc., €915k.
Filing timeline
BuySalePeter Heerma
Insider track record
Disclosed buys
0
Disclosed sells
34
Signal history
Peter Heerma: trading record in brief
Peter Heerma, Chief Commercial Officer of Travere Therapeutics, Inc., has 57 filings from October 2, 2019 to September 17, 2026. The market trades are 34 sales worth EUR 17,189,860, but the median is only EUR 49,798: the three largest carry almost all of it, with EUR 5,132,205 and EUR 4,365,627 on September 16, 2026 and EUR 3,867,502 on September 15, 2026. No purchase.
The rest of the record is 12 grants, 9 option exercises and 2 other lines.
Activity accelerates clearly: 1 filing in 2019, 4 in 2022, 13 in 2025 and 18 in 2026. The last twelve months hold 22, 12 of them sales. Filings come out a median of 2 days after the trade, across all 57 filings. At Travere, Eric M. Dube has trades within 30 days of 32 of Peter Heerma's trades, Elizabeth E. Reed and William E. Rote of 30 each, Sandra Calvin of 23, Christopher R. Cline of 21, always in the same direction.
Companies and markets linked to Peter Heerma
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations57 total
39,283 shares@ US$26.880.022% mcap4.6% of flowCommon StockSEC:0001789617-26-000004:0
1,381 shares@ US$22.400.0007% mcap0.1% of flowCommon StockSEC:0001789617-26-000004:1
93,604 shares@ US$63.24710.12% mcap25.7% of flowCommon StockSEC:0001789617-26-000004:10
71,938 shares@ US$62.05170.094% mcap19.4% of flowCommon StockSEC:0001789617-26-000004:3
1,431 shares@ US$65.30930.0020% mcap0.4% of flowCommon StockSEC:0001789617-26-000004:6
79,113 shares@ US$63.65460.11% mcap21.9% of flowCommon StockSEC:0001789617-26-000004:11
1,400 shares@ US$63.65210.0019% mcap0.4% of flowCommon StockSEC:0001789617-26-000004:5
36,526 shares@ US$8.930.0069% mcap1.4% of flowCommon StockSEC:0001789617-26-000004:2
27,421 shares@ US$62.59360.036% mcap7.5% of flowCommon StockSEC:0001789617-26-000004:4
100,000 shares@ US$11.250.024% mcap4.9% of flowCommon StockSEC:0001789617-26-000004:7
55,000 shares@ US$15.460.018% mcap3.7% of flowCommon StockSEC:0001789617-26-000004:8
17,717 shares@ US$26.880.010% mcap2.1% of flowCommon StockSEC:0001789617-26-000004:9
8,282 shares@ US$22.400.0039% mcap0.8% of flowCommon StockSEC:0001789617-26-000004:12
8,282 shares@ US$65.07090.011% mcap2.4% of flowCommon StockSEC:0001789617-26-000004:13
14,000 shares0Common StockSEC:0001789617-26-000002:0
7,215 shares@ US$41.92880.0054% mcap1.3% of flowCommon StockSEC:0001789617-26-000002:1
7,310 shares@ US$32.121.0% of flowCommon StockSEC:0001789617-26-000001:1
26,120 shares0Common StockSEC:0001789617-26-000001:0
4,980 shares@ US$40.000.8% of flowCommon StockSEC:0001789617-25-000009:0
1,078 shares0Common StockSEC:0001789617-25-000007:1
5,591 shares@ US$35.000.8% of flowCommon StockSEC:0001789617-25-000007:0
2,662 shares@ US$30.000.3% of flowCommon StockSEC:0001789617-25-000006:0
891 shares0Common StockSEC:0001789617-25-000004:0
1,771 shares@ US$21.050.2% of flowCommon StockSEC:0001415889-25-012057:1
4,920 sharesCommon StockSEC:0001415889-25-012057:0
25 of 57 declarations
